A sustained dual drug delivery system for proliferative vitreoretinopathy

References

• Banerjee PJ, Quartilho A, Bunce C, et al. (2017). Slow-release dexamethasone in proliferative vitreoretinopathy: a prospective, randomized controlled clinical trial. Ophthalmology 124:757–67.
   PubMed Web of Science ®Google Scholar
• Cardillo JA, Farah ME, Mitre J, et al. (2004). An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br J Ophthalmol 88:1201–5.
   PubMed Web of Science ®Google Scholar
• Cardillo JA, Stout JT, LaBree L, et al. (1997). Post-traumatic proliferative vitreoretinopathy. The epidemiologic profile, onset, risk factors, and visual outcome. Ophthalmology 104:1166–73.
   PubMed Web of Science ®Google Scholar
• Case JL, Peyman GA, Barrada A, et al. (1985). Clearance of intravitreal 3H-fluorouracil. Ophthalmic Surg 16:378–81.
   PubMedGoogle Scholar
• Charteris DG, Aylward GW, Wong D, et al. (2004). A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology 111:2240–5.
   PubMed Web of Science ®Google Scholar
• Cheng L, Hostetler K, Valiaeva N, et al. (2010). Intravitreal crystalline drug delivery for intraocular proliferation diseases. Invest Ophthalmol Vis Sci 51:474–81.
   PubMed Web of Science ®Google Scholar
• Chhablani J, Nieto A, Hou H, et al. (2013). Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system. Invest Ophthalmol Vis Sci 54:1268–79.
   PubMed Web of Science ®Google Scholar
• Chiba C. (2014). The retinal pigment epithelium: an important player of retinal disorders and regeneration. Exp Eye Res 123:107–14.
   PubMed Web of Science ®Google Scholar
• Fisher SK, Erickson PA, Lewis GP, Anderson DH. (1991). Intraretinal proliferation induced by retinal-detachment. Invest Ophth Vis Sci 32:1739–48.
   PubMed Web of Science ®Google Scholar
• Fisher SK, Lewis GP, Linberg KA, Verardo MR. (2005). Cellular remodeling in mammalian retina: results from studies of experimental retinal detachment. Prog Retin Eye Res 24:395–431.
   PubMed Web of Science ®Google Scholar
• Fisher SK, Lewis GP. (2003). Müller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vision Res 43:887–97.
   PubMed Web of Science ®Google Scholar
• Hou H, Huffman K, Rios S, et al. (2015). A novel approach of daunorubicin application on formation of proliferative retinopathy using a porous silicon controlled delivery system: pharmacodynamics. Invest Ophthalmol Vis Sci 56:2755–63.
   PubMed Web of Science ®Google Scholar
• Hou H, Wang C, Nan K, et al. (2016). Controlled release of dexamethasone from an intravitreal delivery system using porous silicon dioxide. Invest Ophthalmol Vis Sci 57:557–66.
   PubMed Web of Science ®Google Scholar
• Kaneko H, Shimizu H, Tsunekawa T, et al. (2018). The relationship between inflammatory cytokines in the sub-silicone oil fluid and retinal thickness in eyes with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Invest Ophth Vis Sci 59:5307.
   Web of Science ®Google Scholar
• Kizhakkethara I, Li X, el-Sayed S, et al. (1995). Noninvasive monitoring of intraocular pharmacokinetics of daunorubicin using fluorophotometry. Int Ophthalmol 19:363–7.
   PubMed Web of Science ®Google Scholar
• Kuo HK, Chen YH, Wu PC, et al. (2012). Attenuated glial reaction in experimental proliferative vitreoretinopathy treated with liposomal doxorubicin. Invest Ophthalmol Vis Sci 53:3167–74.
   PubMedGoogle Scholar
• Kwon OW, Song JH, Roh MI. (2016). Retinal detachment and proliferative vitreoretinopathy. Dev Ophthalmol 55:154–62.
   PubMedGoogle Scholar
• Lewis GP, Chapin EA, Byun J, et al. (2009). Muller cell reactivity and photoreceptor cell death are reduced after experimental retinal detachment using an inhibitor of the Akt/mTOR pathway. Invest Ophthalmol Vis Sci 50:4429–35.
   PubMed Web of Science ®Google Scholar
• Lewis GP, Chapin EA, Luna G, et al. (2010). The fate of Muller’s glia following experimental retinal detachment: nuclear migration, cell division, and subretinal glial scar formation. Mol Vis 16:1361–72.
   PubMed Web of Science ®Google Scholar
• Mietz H, Heimann K. (1995). Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal diseases. Brit J Ophthalmol 79:874–7.
   PubMed Web of Science ®Google Scholar
• Nieto A, Hou H, Sailor MJ, et al. (2013). Ocular silicon distribution and clearance following intravitreal injection of porous silicon microparticles. Exp Eye Res 116:161–8.
   PubMed Web of Science ®Google Scholar
• Pennock S, Haddock LJ, Eliott D, et al. (2014). Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res 40:16–34.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Marigliani D, Romeo N, Toti P. (2014). Disease pathways in proliferative vitreoretinopathy: an ongoing challenge. J Cell Physiol 229:1577–83.
   PubMed Web of Science ®Google Scholar
• Wang C, Hou H, Nan K, et al. (2014). Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp Eye Res 129:74–82.
   PubMed Web of Science ®Google Scholar
• Warther D, Xiao Y, Li FT, et al. (2018). Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy. Drug Deliv 25:1537–45.
   PubMed Web of Science ®Google Scholar
• Wickham L, Bunce C, Wong D, et al. (2007). Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 114:698–704.
   PubMed Web of Science ®Google Scholar
• Wiedemann P, Hilgers RD, Bauer P, Heimann K. (1998). Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 126:550–9.
   PubMed Web of Science ®Google Scholar
• Willis JR, Doan QV, Gleeson M, et al. (2017). Vision-related functional burden of diabetic retinopathy across severity levels in the United States. Jama Ophthalmol 135:926–32.
   PubMed Web of Science ®Google Scholar
• Wubben TJ, Besirli CG, Zacks DN. (2016). Pharmacotherapies for retinal detachment. Ophthalmology 123:1553–62.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Ishiguro S, Tamai M. (1993). Expression of glial fibrillary acidic protein in rabbit Muller cells after lensectomy-vitrectomy. Invest Ophth Vis Sci 34:3154–60.
   PubMed Web of Science ®Google Scholar
• Yu Z, Ma S, Wu M, et al. (2020). Self-assembling hydrogel loaded with 5-FU PLGA microspheres as a novel vitreous substitute for proliferative vitreoretinopathy. J Biomed Mater Res Part A.doi: 10.1002/jbm.a.36995.
   Google Scholar
• Zahn G, Volk K, Lewis GP, et al. (2010). Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci 51:1028–35.
   PubMed Web of Science ®Google Scholar
• Zhao M, Bousquet E, Valamanesh F, et al. (2011). Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophth Vis Sci 52:6340–7.
   PubMed Web of Science ®Google Scholar